Humira shows promise for Long-Term control of Kids' colitis
NCT ID NCT02632175
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety and effectiveness of adalimumab (Humira) in 59 children with ulcerative colitis who had already completed a previous trial. The children received injections every other week or weekly. Researchers tracked side effects and how well the drug controlled disease symptoms using standard scoring tools. The goal was to see if adalimumab remains safe and effective over an extended period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adalimumab (Humira)
What this could lead to
If successful, this could confirm that adalimumab is a safe long-term option to control ulcerative colitis in children, reducing flare-ups and improving daily life.
What could go wrong
This is a small, open-label study (no placebo) with only 59 children, so results may not apply to all patients. Long-term use of adalimumab carries risks like serious infections and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arnold Palmer Hospital /ID# 147295
Orlando, Florida, 32806, United States
-
Centrum Zdrowia MDM /ID# 147280
Warsaw, Masovian Voivodeship, 00-189, Poland
-
Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 147290
London, Greater London, E1 2ES, United Kingdom
-
Duplicate_The Royal Free London NHS Foundation Trust /ID# 147292
London, Greater London, NW3 2QG, United Kingdom
-
Gabinet Lekarski Bartosz Korcz /ID# 147281
Rzeszów, Podkarpackie Voivodeship, 35-210, Poland
-
Hospital Universitario Vall d'Hebron /ID# 147288
Barcelona, 08035, Spain
-
Instytut Centrum Zdrowia Matki Polki /ID# 169017
Lodz, Łódź Voivodeship, 93-338, Poland
-
Juntendo University Hospital /ID# 147315
Bunkyo-ku, Tokyo, 113-8431, Japan
-
Kurume University Hospital /ID# 145710
Kurume-shi, Fukuoka, 830-0011, Japan
-
MNGI Digestive Health, P. A. /ID# 147294
Minneapolis, Minnesota, 55413-2195, United States
-
Mayo Clinic - Rochester /ID# 147304
Rochester, Minnesota, 55905-0001, United States
-
MultiCare Institute Health System /ID# 169005
Tacoma, Washington, 98405, United States
-
National Center for Child Health and Development /ID# 147312
Setagaya-ku, Tokyo, 157-8535, Japan
-
Univerzitna nemocnica Martin /ID# 147283
Martin, Žilina Region, 036 01, Slovakia
-
Uniwersytecki Szpital Dzieciecy w Krakowie /ID# 147279
Krakow, Lesser Poland Voivodeship, 30-663, Poland
-
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego /ID# 147310
Wroclaw, Lower Silesian Voivodeship, 50-369, Poland